Related references
Note: Only part of the references are listed.Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy
L. Brilli et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients
Edwin A. Basak et al.
THYROID (2020)
BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION
Rena M. Pollack et al.
ENDOCRINE PRACTICE (2019)
Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
Alessandro Brancatella et al.
EUROPEAN THYROID JOURNAL (2019)
Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution
F. Guaraldi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Hye In Kim et al.
ONCOIMMUNOLOGY (2018)
Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Practical Recommendations for Diagnosis and Clinical Management
Romualdo Barroso-Sousa et al.
CANCER (2018)
Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers
Melissa G. Lechner et al.
THYROID (2018)
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Anna Buda-Nowak et al.
MEDICAL ONCOLOGY (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
Jeroen de Filette et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The incidence and prevalence of thyroid autoimmunity
Donald S. A. McLeod et al.
ENDOCRINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
The incidence of autoimmune thyroid disease: a systematic review of the literature
Anita McGrogan et al.
CLINICAL ENDOCRINOLOGY (2008)
Share Paper
